{
  "figure_1": "Citation disposition for the literature search",
  "figure_2": "Growth in publications related to biosimilar switching, from 1993 to 2016",
  "figure_3": "Types of study designs across larger and smaller biologics. Biosimilars of adalimumab, etanercept, and rituximab were approved as of the cut-off date for manuscript. However, there was likely insufficient time for completion and publication of RWE with etanercept and rituximab, and a biosimilar adalimumab was not marketed as of the cut-off date. RCT randomized clinical trial, RWE real world evidence, rHuEPO recombinant human erythropoietin, GH growth hormone",
  "figure_4": "Switching study design for biosimilar filgrastim (EP2006) versus reference medicine. d day, DSN duration of severe neutropenia",
  "figure_5": "Switching study design for biosimilar etanercept (GP2015) versus reference medicine. wk week"
}